Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.47 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.47 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18410317 | 0.92 | HTR2C (0.56) | HTR2CCACNA1GCACNA1HCACNA1ISMN1; SMN2 | |
| SCHEMBL20296331 | 0.92 | HTR2C (0.56) | HTR2CCACNA1GCACNA1HCACNA1ISMN1; SMN2 | |
| SCHEMBL11104941 | 0.89 | HTR2C (0.52) | HTR2CCACNA1GCACNA1HCACNA1ISMN1; SMN2 | |
| SCHEMBL11109029 | 0.89 | HTR2C (0.52) | HTR2CCACNA1GCACNA1HCACNA1ISMN1; SMN2 | |
| SCHEMBL11104947 | 0.89 | HTR2C (0.52) | HTR2CCACNA1GCACNA1HCACNA1ISMN1; SMN2 | |
| SCHEMBL7646354 | 0.87 | HTR2C (0.63) | HTR2CCACNA1GCACNA1HCACNA1IHCRTR2 | |
| SCHEMBL1509015 | 0.87 | HTR2C (0.63) | HTR2CCACNA1GCACNA1HCACNA1IHCRTR2 | |
| SCHEMBL7950602 | 0.87 | HTR2C (0.63) | HTR2CCACNA1GCACNA1HCACNA1IHCRTR2 | |
| SCHEMBL6121028 | 0.87 | HTR2C (0.63) | HTR2CCACNA1GCACNA1HCACNA1IHCRTR2 | |
| SCHEMBL6121024 | 0.87 | HTR2C (0.63) | HTR2CCACNA1GCACNA1HCACNA1IHCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273239-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180179217-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-06-28 | — | — | US | disclosed |
| US-20180179217-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-06-28 | — | — | US | disclosed |
| US-9758525-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758525-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758525-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20150368253-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2015-12-24 | — | — | US | disclosed |
| US-20150368253-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2015-12-24 | — | — | US | disclosed |
| US-20150368253-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2015-12-24 | — | — | US | disclosed |
| EP-2951184-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | Aptinyx Inc. (US) | 2015-12-09 | — | — | EP | disclosed |
| WO-2014120786-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014120786-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368253-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | HTR2C 133/4885CACNA1G 260/4885CACNA1H 294/4885 |
| US-10273239-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | HTR2C 133/4885CACNA1G 260/4885CACNA1H 294/4885 |
| US-20180179217-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | HTR2C 133/4885CACNA1G 260/4885CACNA1H 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.